3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Lung Diseases
2
Lung Neoplasms
1
Carcinoma
1
Interventions
Carboplatin
9
Pemetrexed
7
pembrolizumab
4
osimertinib
3
entinostat
3
Gemcitabine
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
camrelizumab
2
Paclitaxel
2
Erlotinib Hydrochloride
2
Cisplatin
2
Bronchoscopy
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
ficlatuzumab
1
exemestane
1
demcizumab
1
cobimetinib
1
ceralasertib
1
atezolizumab
1
alectinib
1
aflibercept
1
Vinorelbine
1
Toll-Like Receptor 1
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lung Diseases
×
zipalertinib
×
Clear all
NCT05967689
2026-05-28
REZILIENT2
Taiho Oncology, Inc.
Phase 2
Recruiting
220 enrolled
NCT05973773
2026-05-28
REZILIENT3
Taiho Oncology, Inc.
Phase 3
Active not recruiting
285 enrolled